Medical Journal of The Islamic Republic of Iran (MJIRI)
Iran University of Medical Sciences
Fri, Jan 30, 2026
[Archive]
Volume 39, Issue 1 (1-2025)
Med J Islam Repub Iran 2025 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bahramirad J, Moradi Y, Moradi G, Dehghanbanadaki H, Abdi M, Nasseri S. Diagnostic Accuracy of CircRNAs for Detecting Gastrointestinal Cancers: An Updated Meta-analysis. Med J Islam Repub Iran 2025; 39 (1) :1421-1436
URL: http://mjiri.iums.ac.ir/article-1-9107-en.html
URL: http://mjiri.iums.ac.ir/article-1-9107-en.html
Jila Bahramirad 
, Yousef Moradi , Ghobad Moradi , Hojat Dehghanbanadaki , Mohammad Abdi , Sherko Nasseri
, Yousef Moradi , Ghobad Moradi , Hojat Dehghanbanadaki , Mohammad Abdi , Sherko Nasseri
Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran & Departments of Molecular Medicine and Medical Biotechnology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran , sherko.naseri@yahoo.com
Abstract: (12 Views)
Background: Gastrointestinal (GI) cancers remain a leading cause of cancer-related mortality worldwide, underscoring the urgent need for reliable, non-invasive diagnostic biomarkers. Circular RNAs (circRNAs), characterized by high stability and tissue specificity, have emerged as promising molecular indicators for early cancer detection. This study aimed to evaluate the diagnostic accuracy of circular RNAs (circRNAs) for detecting gastrointestinal (GI) cancers, including gastric cancer (GC), hepatocellular carcinoma (HCC), esophageal cancer (EC), colorectal cancer (CRC), and pancreatic cancer (PC).
Methods: A comprehensive literature search was conducted in PubMed, Web of Science, Scopus, and EMBASE up to December 2024, following PRISMA guidelines. Quality assessment was performed using the QUADAS-2 tool. Diagnostic accuracy metrics were analyzed using Metandi and Midas modules in STATA 17.
Results: From 9,733 retrieved articles, 139 studies involving 25,847 participants and 153 circRNAs met inclusion/exclusion criteria. No new eligible studies were identified from July 2021 to December 2024. The pooled diagnostic performance of circRNAs for gastrointestinal cancers was: sensitivity 0.78 (95% CI: 0.76–0.79), specificity 0.76 (95% CI: 0.74–0.77), PLR 3.3 (95% CI: 3.1–3.5), NLR 0.29 (95% CI: 0.27–0.31), and AUC 0.83 (95% CI: 0.80–0.85). Specific circRNAs (e.g., hsa_circ_0001017, circ-SLC7A5, circ-LDLRAD3) showed promising diagnostic performance.
Conclusion: CircRNAs exhibit good diagnostic accuracy for hepatocellular carcinoma (AUC 0.83) and esophageal cancer (AUC 0.81), moderate-to-good accuracy for gastric cancer (AUC 0.79) and pancreatic cancer (AUC 0.78), but limited accuracy for colorectal cancer (AUC 0.68), highlighting their potential as non-invasive biomarkers, particularly for HCC and EC, with further validation needed to enhance clinical utility.
Methods: A comprehensive literature search was conducted in PubMed, Web of Science, Scopus, and EMBASE up to December 2024, following PRISMA guidelines. Quality assessment was performed using the QUADAS-2 tool. Diagnostic accuracy metrics were analyzed using Metandi and Midas modules in STATA 17.
Results: From 9,733 retrieved articles, 139 studies involving 25,847 participants and 153 circRNAs met inclusion/exclusion criteria. No new eligible studies were identified from July 2021 to December 2024. The pooled diagnostic performance of circRNAs for gastrointestinal cancers was: sensitivity 0.78 (95% CI: 0.76–0.79), specificity 0.76 (95% CI: 0.74–0.77), PLR 3.3 (95% CI: 3.1–3.5), NLR 0.29 (95% CI: 0.27–0.31), and AUC 0.83 (95% CI: 0.80–0.85). Specific circRNAs (e.g., hsa_circ_0001017, circ-SLC7A5, circ-LDLRAD3) showed promising diagnostic performance.
Conclusion: CircRNAs exhibit good diagnostic accuracy for hepatocellular carcinoma (AUC 0.83) and esophageal cancer (AUC 0.81), moderate-to-good accuracy for gastric cancer (AUC 0.79) and pancreatic cancer (AUC 0.78), but limited accuracy for colorectal cancer (AUC 0.68), highlighting their potential as non-invasive biomarkers, particularly for HCC and EC, with further validation needed to enhance clinical utility.
Type of Study: Meta-analysis Article |
Subject:
Gastroenterology
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
